Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience

Bone

Volumn 32, Issue 2, 2003, Pages 120-126

  Sorensen, O H ^a   Crawford, G M ^b   Mulder, H ^c   Hosking, D J ^d   Gennari, C ^e   Mellstrom, D ^f   Pack, S ^g   Wenderoth, D ^g   Cooper, C ^h   Reginster, J Y ⁱ  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Community Pharmacology Services ^*  (United Kingdom)

^c Osteosupport   (Netherlands)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SIENA   (Italy)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g PROCTER AND GAMBLE COMPANY   (United States)

^h UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

ⁱ UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bisphosphonate; Bone mineral density; Postmenopausal osteoporosis; Risedronate; Vertebral fracture

Indexed keywords

PLACEBO; RISEDRONIC ACID;

ABDOMINAL PAIN; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ESOPHAGITIS; ESOPHAGUS ULCER; FEMALE; GASTRITIS; GASTROINTESTINAL TOXICITY; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; SPINE; STOMACH ULCER; VERTEBRA FRACTURE;

EID: 0037291756     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(02)00946-8     Document Type: Article

References (10)

1. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis; a randomized controlled trial. J Am Med Assoc. 282:1999;1344-1352.
2. Reginster J.-Y., Minne H., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 11:2000;83-91.
3. McClung M.R., Geusens P., Miller P.D., Zippel H., Gensen W.G., Roux C., et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 344:2001;333-340.
4. Heaney R.P., Zizic T.M., Fogelman I., Olszynski W.P., Geusens P., Kasibhatla C., et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int. 13:2002;501-505.
5. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. J Am Med Assoc. 280:1998;2077-2082.
6. Miller P.D., Watts N.B., Licata A.A., Harris S.T., Genant H.K., Wasnich R.D., et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis efficacy and safety after 7 years of treatment . Am J Med. 103:1997;468-478.
7. Ott S.M. Fractures, after long-term alendronate therapy. J Clin Endocrinol Metab. 86:2001;1835.
8. Tonino R.P., Meunier P.J., Emkey R., Rodriguez-Portales J.A., Menkes C.-J., Wasnich R.D., et al. Skeletal benefits of alendronate 7-year treatment of postmenopausal osteoporotic women . J Clin Endocrinol Metab. 85:2000;3109-3115.
9. nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto . J Bone Miner Res. 15:(Suppl 1):2000;S229.
10. Chesnut C.H., Silverman S.I., Andriano K., Genant H., Gimona A.J., Harris S., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis the prevent recurrence of osteoporotic fractures study . Am J Med. 109:2000;267-276.